
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed o... Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE). 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.08 | -7.47663551402 | 1.07 | 1.1395 | 0.89 | 67453 | 0.99282806 | CS |
4 | -0.23 | -18.8524590164 | 1.22 | 1.78 | 0.89 | 142294 | 1.32238698 | CS |
12 | -0.35 | -26.1194029851 | 1.34 | 1.78 | 0.89 | 61711 | 1.29761308 | CS |
26 | -0.07 | -6.60377358491 | 1.06 | 1.78 | 0.63 | 100965 | 1.19353879 | CS |
52 | -0.0065 | -0.652282990467 | 0.9965 | 3.23 | 0.63 | 79669 | 1.41421773 | CS |
156 | -4.22 | -80.9980806142 | 5.21 | 5.62 | 0.63 | 76198 | 1.52979587 | CS |
260 | -4.22 | -80.9980806142 | 5.21 | 5.62 | 0.63 | 76198 | 1.52979587 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관